Canntab Therapeutics Limited (CTABF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Canntab Therapeutics Limited (CTABF) with AI Score 52/100 (Grade B). Canntab Therapeutics Limited is a Canadian phytopharmaceutical company specializing in the research and development of advanced pharmaceutical-grade oral cannabinoid formulations. Sector: Healthcare.
Last analyzed: Jun 15, 2026CTABF: the 6 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Canntab Therapeutics Limited (CTABF) Healthcare & Pipeline Overview
Canntab Therapeutics Limited, a Canadian phytopharmaceutical firm, specializes in developing and distributing advanced pharmaceutical-grade oral cannabinoid formulations. The company targets various medical conditions, including pain, sleep disorders, and addiction, aiming to provide standardized, precise dosing alternatives within the evolving healthcare sector.
What Is the Investment Thesis for CTABF?
Canntab Therapeutics Limited presents a research focus on the burgeoning medical cannabis sector, specifically targeting the development of pharmaceutical-grade oral cannabinoid formulations. The company's value proposition centers on its commitment to standardized, precise dosing, which could address a critical need in the medical community for reliable and consistent cannabinoid therapies. Key growth catalysts include the ongoing expansion and increasing acceptance of medical cannabis globally, coupled with a rising demand for non-inhalable, discreet, and accurately dosed products. The company's diverse product pipeline, encompassing sustained-release, immediate-release, and multi-layer tablets, positions it to potentially capture market share across various therapeutic applications, from chronic pain and sleep disorders to addiction treatment. However, the investment thesis is tempered by significant operational and market risks. The company currently operates with a substantial negative Profit Margin of -1257.5% and a Market Cap of $0.00B, indicating a pre-revenue or early-stage development phase with considerable unprofitability. Its Gross Margin of 23.7% suggests some revenue generation, but operational costs far outweigh it. Furthermore, the highly regulated and rapidly evolving cannabis industry presents ongoing regulatory uncertainty and intense competition. Trading on the OTC Other tier also introduces liquidity and transparency challenges. Future success hinges on its ability to secure regulatory approvals, scale production, achieve market penetration, and ultimately transition to profitability amidst these considerable headwinds.
Based on FMP financials and quantitative analysis
CTABF Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or pre-revenue stage company.
- Profit Margin: -1257.5%, reflecting significant operational losses and unprofitability.
- Gross Margin: 23.7%, suggesting some revenue generation from product sales, but insufficient to cover operating expenses.
- Core Business: Focuses on the research and development of advanced pharmaceutical-grade oral cannabinoid formulations.
- Therapeutic Focus: Products designed to treat a wide range of conditions including sleep disorders, pain management, and addiction.
Who Are CTABF's Competitors?
CTABF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CTABF's Key Strengths?
- Specialization in advanced pharmaceutical-grade oral cannabinoid formulations.
- Diverse product pipeline with various oral delivery technologies (sustained-release, flash-melt, bi-layer).
- Focus on standardized and precise dosing, appealing to medical professionals and patients.
- Addresses a wide range of significant medical conditions, including pain, sleep, and addiction.
What Are CTABF's Weaknesses?
- Significant unprofitability with a Profit Margin of -1257.5%.
- Market capitalization of $0.00B, indicating a very early stage or micro-cap status.
- Trading on the OTC Other tier, which implies lower liquidity and transparency.
- Limited information available on CEO background and company's founding history.
What Could Drive CTABF Stock Higher?
- Potential for new product launches or expanded therapeutic indications for existing formulations.
- Regulatory advancements or favorable policy changes within the Canadian medical cannabis sector.
- Continued research and development efforts leading to patent filings or clinical trial progress for advanced cannabinoid formulations.
- Formation of strategic partnerships or distribution agreements to enhance market reach and commercialization efforts.
What Are the Key Risks for CTABF?
- Financial-distress signal — its Altman Z-Score of -39.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -1257.5% Profit Margin, posing a challenge to long-term sustainability.
- High regulatory uncertainty and evolving legal frameworks within the global and Canadian cannabis industry.
- Intense competition from well-capitalized pharmaceutical companies and established cannabis producers.
- Challenges in securing additional capital or maintaining sufficient liquidity, particularly given its $0.00B Market Cap and OTC Other trading status.
- Market acceptance and adoption rates of its specialized cannabinoid formulations may be slower than anticipated.
What Are the Growth Opportunities for CTABF?
- Expansion in Medical Cannabis Market Adoption: The global medical cannabis market continues to expand as more jurisdictions legalize its use and scientific research provides further validation for its therapeutic applications. Canntab, with its focus on pharmaceutical-grade oral formulations, is well-positioned to capitalize on this growing acceptance among both patients and healthcare professionals who prioritize standardized, reliable dosing. This market is projected to reach significant valuations, with estimates often exceeding tens of billions of dollars globally in the coming years, offering a substantial addressable market for Canntab's specialized products. The timeline for this growth is ongoing, driven by evolving regulatory frameworks and increasing patient awareness.
- Increasing Demand for Standardized Oral Dosage Forms: There is a discernible trend in the medical community towards cannabinoid products that offer precise and consistent dosing, moving away from less predictable methods like smoking or edibles. Canntab's portfolio of sustained-release, immediate-release, and multi-layer tablets directly addresses this demand, providing healthcare providers with tools for more controlled patient treatment. This focus on pharmaceutical-grade oral delivery systems enhances patient compliance and safety, potentially opening doors to broader clinical adoption. The market for such precision-dosed products is a critical segment within the overall medical cannabis market, valued for its therapeutic consistency.
- Diversification into New Therapeutic Applications: Canntab's current product pipeline targets a range of conditions including pain, sleep disorders, and addiction. However, ongoing research into cannabinoids continues to uncover potential applications in other therapeutic areas, such as neurological disorders, inflammatory conditions, and oncology support. By leveraging its expertise in advanced formulation development, Canntab has the opportunity to expand its product offerings into these emerging indications, thereby broadening its addressable market and revenue streams. This diversification would allow the company to tap into new patient populations and capitalize on evolving medical understanding of cannabinoids, with a long-term development timeline.
- Strategic Partnerships and Distribution Expansion: To accelerate market penetration and overcome the challenges associated with being a smaller entity, Canntab has the opportunity to forge strategic partnerships with larger pharmaceutical distributors, healthcare networks, or established cannabis companies. Such collaborations could significantly enhance its reach, streamline regulatory processes, and provide access to broader patient bases across Canada and potentially internationally. These partnerships could also facilitate co-development agreements, leveraging external R&D capabilities or manufacturing infrastructure, thereby reducing internal capital expenditure and accelerating product commercialization. The timeline for such opportunities is continuous, dependent on market conditions and partnership viability.
- Innovation in Drug Delivery Technology: Canntab's existing focus on various oral dosage forms like flash-melt and bi-layer tablets demonstrates its commitment to innovative drug delivery. Continuous investment in research and development to create next-generation cannabinoid formulations, potentially incorporating novel excipients or advanced encapsulation techniques, represents a significant growth opportunity. Such innovations could lead to improved bioavailability, enhanced patient experience, or proprietary advantages that differentiate Canntab's products in a competitive market. Developing unique delivery systems could also create intellectual property, providing a competitive moat and opening licensing opportunities, with a long-term development and commercialization timeline.
What Opportunities Does CTABF Have?
- Growing global acceptance and legalization of medical cannabis.
- Increasing demand for standardized, pharmaceutical-grade cannabinoid products.
- Potential to expand into new therapeutic areas as cannabinoid research progresses.
- Strategic partnerships could enhance distribution, R&D, and market reach.
What Threats Does CTABF Face?
- Ongoing regulatory uncertainty and evolving legal frameworks in the cannabis industry.
- Intense competition from both established pharmaceutical companies and other cannabis producers.
- Challenges in securing additional capital given current financial performance and market cap.
- Potential for new entrants or disruptive technologies to impact market share.
What Are CTABF's Competitive Advantages?
- Specialization in advanced pharmaceutical-grade oral cannabinoid formulations, distinguishing from generic cannabis products.
- Proprietary development of diverse oral delivery technologies, including sustained-release, flash-melt, and bi-layer tablets.
- Focus on standardized and precise dosing, which appeals to the medical community and enhances therapeutic reliability.
- Targeting specific medical conditions with tailored formulations, creating a niche in the phytopharmaceutical market.
What Does CTABF Do?
Canntab Therapeutics Limited is a phytopharmaceutical company headquartered in Markham, Canada, dedicated to the research and development of advanced pharmaceutical-grade formulations of cannabinoids. The company's core mission revolves around providing precise, standardized oral dosage forms of cannabis, distinguishing itself from traditional consumption methods. Canntab's product portfolio encompasses a range of innovative oral solutions designed to address diverse medical needs. These include sustained release cannabinoid formulations and pellets, engineered to provide prolonged therapeutic effects, and immediate release cannabidiol formulations for rapid onset of action. Furthermore, the company develops modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations for quick dissolution, and bi-layer cannabinoid tablets, each tailored for specific patient requirements and therapeutic profiles. These advanced formulations are developed to treat a wide array of medical conditions. Canntab targets sleep disorders, offering solutions that aim to improve sleep quality and duration. For mental health, the company addresses post-traumatic stress disorder (PTSD) and social anxiety, leveraging cannabinoids' potential anxiolytic properties. In the realm of chronic conditions, Canntab's products are designed for arthritis and general pain management, providing alternatives to conventional analgesics. The company also focuses on alleviating symptoms associated with cancer treatments, such as pain management and appetite loss, and is actively involved in addiction treatment therapy for opioids and other painkillers, aiming to support recovery and reduce reliance on highly addictive substances. By focusing on pharmaceutical-grade products and standardized dosing, Canntab Therapeutics Limited positions itself to appeal to medical users and healthcare professionals seeking reliable and consistent cannabinoid therapies within the highly regulated and evolving cannabis industry.
What Products and Services Does CTABF Offer?
- Researches and develops advanced pharmaceutical-grade formulations of cannabinoids.
- Offers a range of oral dosage forms, including sustained release cannabinoid formulations and pellets.
- Provides immediate release cannabidiol formulations for rapid therapeutic effects.
- Develops modified-release multi-layer cannabinoid formulations for tailored drug delivery.
- Creates flash-melt cannabinoid formulations designed for quick dissolution.
- Produces bi-layer cannabinoid tablets, combining different release profiles or active ingredients.
- Targets treatment for conditions such as sleep disorders, post-traumatic stress disorder, and social anxiety.
- Addresses general pain, arthritis, pain management, and appetite loss associated with cancer treatments.
- Engages in addiction treatment therapy for opioids and other painkillers.
- Headquartered in Markham, Canada, focusing its operations within the Canadian market.
How Does CTABF Make Money?
- Develops and commercializes specialized pharmaceutical-grade oral cannabinoid products.
- Generates revenue through the sale of its proprietary cannabinoid formulations to medical patients and healthcare providers.
- Invests in ongoing research and development to innovate new delivery methods and therapeutic applications for cannabinoids.
- Aims to differentiate itself through standardized dosing and high-quality, consistent product manufacturing.
What Industry Does CTABF Operate In?
Canntab Therapeutics Limited operates within the dynamic and evolving healthcare sector, specifically positioned in the Drug Manufacturers - Specialty & Generic industry with a focus on phytopharmaceuticals. The broader medical cannabis market is experiencing significant growth driven by increasing legalization, scientific research validating therapeutic benefits, and a growing patient demand for alternative and complementary medicines. A key trend within this landscape is the shift towards pharmaceuticalization of cannabis, where emphasis is placed on standardized dosing, consistent product quality, and rigorous clinical validation, moving away from recreational or unregulated markets. Canntab's strategy aligns with this trend by developing advanced oral dosage formulations of cannabinoids, aiming to provide precision and reliability akin to traditional pharmaceuticals. The competitive landscape includes both established pharmaceutical companies exploring cannabinoid-based drugs and numerous cannabis cultivators and product manufacturers. Canntab differentiates itself by specializing in specific oral delivery technologies and pharmaceutical-grade standards, aiming to carve out a niche in the medical segment where precise and consistent therapeutic outcomes are paramount.
Who Are CTABF's Key Customers?
- Medical patients seeking precise and consistent cannabinoid therapies for various conditions.
- Healthcare professionals, including doctors and specialists, who prescribe medical cannabis.
- Licensed pharmacies and medical cannabis dispensaries that distribute pharmaceutical products.
- Individuals seeking non-inhalable, discreet, and accurately dosed alternatives for cannabis consumption.
Company Profile
Canntab Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Markham, CA. The company is led by CEO Richard C. Goldstein. CTABF has traded publicly since 2017.
Canntab Therapeutics Limited (CTABF) Valuation Context
Relative to its peer group, CTABF's quantitative score of 52/100 is below the peer average of 66/100.
F-Score 3/9Financial Health
Canntab Therapeutics Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.49 places it in the distress zone, a signal of elevated financial risk.
CTABF Financials
Bull Case vs Bear Case
Bull Case
- Specialization in advanced pharmaceutical-grade oral cannabinoid formulations.
- Diverse product pipeline with various oral delivery technologies (sustained-release, flash-melt, bi-layer).
- Focus on standardized and precise dosing, appealing to medical professionals and patients.
- Addresses a wide range of significant medical conditions, including pain, sleep, and addiction.
Bear Case
- Significant unprofitability with a Profit Margin of -1257.5%.
- Market capitalization of $0.00B, indicating a very early stage or micro-cap status.
- Trading on the OTC Other tier, which implies lower liquidity and transparency.
- Limited information available on CEO background and company's founding history.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
CTABF Latest News
No recent news available for CTABF.
CTABF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTABF.
Price Targets
Wall Street price target analysis for CTABF.
CTABF MoonshotScore
What does this score mean?
The MoonshotScore rates CTABF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard C. Goldstein
Unknown
Unknown. Information regarding Richard C. Goldstein's specific career history, educational background, and previous roles prior to his leadership at Canntab Therapeutics Limited is not provided in the available source data. His professional credentials and detailed experience remain undisclosed.
Track Record: Unknown. Specific achievements, strategic decisions, or significant company milestones directly attributable to Richard C. Goldstein's leadership at Canntab Therapeutics Limited are not detailed in the provided information. The available data does not outline key successes or strategic directions implemented under his tenure.
CTABF OTC Market Information
Canntab Therapeutics Limited trades on the OTC Other tier, which is the lowest of the three primary OTC Markets tiers (OTCQX, OTCQB, and OTC Pink/Other). Companies on the OTC Other tier are typically micro-cap or penny stocks that do not meet the minimum financial or disclosure requirements for OTCQX or OTCQB. This tier is characterized by minimal public disclosure, often lacking audited financials or comprehensive reporting, making it challenging for investors to access transparent company information. Trading on this tier generally implies higher risk and less regulatory oversight compared to major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making comprehensive due diligence challenging.
- Significantly higher price volatility and wider bid-ask spreads due to low trading volume.
- Increased susceptibility to market manipulation and fraudulent activities due to less regulatory oversight.
- Difficulty in accessing capital for growth and operations, potentially leading to dilution or financial distress.
- Potential for delisting or further restrictions if disclosure requirements are not met or financial health deteriorates.
- Verify the company's current financial statements, if any are publicly available, directly from official sources.
- Research any recent news, press releases, or corporate actions beyond what is easily accessible.
- Investigate the backgrounds of key management personnel and board members for credibility.
- Assess the company's business model and competitive landscape for long-term viability.
- Understand the specific regulatory environment for phytopharmaceuticals in Canada and potential changes.
- Evaluate the company's intellectual property and any patents related to its formulations.
- Consider the potential for dilution from future capital raises or stock issuances.
- Focus on research and development of pharmaceutical-grade products, suggesting a scientific approach.
- Headquartered in Markham, Canada, indicating a physical presence and operational base.
- Clear articulation of specific products (e.g., sustained release, flash-melt tablets) and therapeutic targets.
- Operating in a legitimate, albeit highly regulated, industry (medical cannabis/phytopharmaceuticals).
Common Questions About CTABF (Healthcare)
What does Canntab Therapeutics Limited do?
Canntab Therapeutics Limited is a Canadian phytopharmaceutical company that specializes in the research, development, and distribution of advanced pharmaceutical-grade oral cannabinoid formulations. The company's core business involves creating precise, standardized dosage forms of cannabis, such as sustained-release pellets, immediate-release cannabidiol formulations, modified-release multi-layer tablets, flash-melt tablets, and bi-layer tablets. These products are designed to treat a diverse range of medical conditions, including sleep disorders, post-traumatic stress disorder, social anxiety, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction therapy for opioids. Canntab aims to provide reliable and consistent therapeutic options within the medical cannabis sector.
What are the key growth opportunities for CTABF in the healthcare sector?
Canntab Therapeutics Limited has several key growth opportunities within the healthcare sector. Firstly, the expanding global acceptance and legalization of medical cannabis present a significant market opportunity, as more patients and healthcare providers seek regulated cannabinoid therapies. Secondly, there is a growing demand for standardized, pharmaceutical-grade oral dosage forms that offer precise and consistent dosing, which is Canntab's core specialization. This focus enhances patient safety and therapeutic reliability. Thirdly, ongoing research into cannabinoids may uncover new therapeutic applications, allowing Canntab to diversify its product pipeline beyond current indications like pain and sleep disorders. Lastly, strategic partnerships could accelerate market penetration and expand distribution channels.
What are the main risks associated with investing in CTABF, particularly given its OTC status?
Investing in Canntab Therapeutics Limited carries several significant risks. Financially, the company exhibits substantial unprofitability, with a Profit Margin of -1257.5%, indicating high operational costs relative to revenue. Its $0.00B Market Cap suggests a very early stage or micro-cap status, often associated with higher investment risk. Furthermore, operating in the cannabis industry exposes CTABF to ongoing regulatory uncertainty and intense competition. Specific to its OTC Other trading status, investors face risks of low liquidity, wide bid-ask spreads, and limited public disclosure, making it challenging to obtain comprehensive financial and operational information. These factors can lead to high price volatility and difficulty in executing trades.
What are the key factors to evaluate for CTABF?
Canntab Therapeutics Limited (CTABF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does CTABF data refresh on this page?
CTABF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CTABF's recent stock price performance?
Canntab Therapeutics Limited (CTABF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in advanced pharmaceutical-grade oral cannabinoid formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CTABF overvalued or undervalued right now?
Valuing Canntab Therapeutics Limited (CTABF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CTABF?
Before investing in Canntab Therapeutics Limited (CTABF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to provided source data. Specific details regarding CEO background, founding story, and detailed financial breakdowns beyond top-line metrics were not available. Competitor tickers were not provided in the source data.